Voyager Therapeutics (VYGR) Current Leases (2019 - 2026)

Voyager Therapeutics (VYGR) has 8 years of Current Leases data on file, last reported at $7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Current Leases fell 0.9% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $7.4 million (down 0.9% YoY), and the FY2025 full-year result was $7.8 million, up 8.48% from the prior year.
• Current Leases eased to $7.4 million in Q1 2026, from $7.8 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $7.8 million in Q3 2025 to a low of $2.5 million in Q2 2022.
• A 5-year average of $5.4 million and a median of $5.9 million in 2024 frame the typical range for Current Leases.
• Across the five-year window, Current Leases slumped 49.17% in 2022 and soared 125.84% in 2024, its largest moves.
• Tracing VYGR's Current Leases over 5 years: stood at $2.8 million in 2022, then advanced by 12.99% to $3.2 million in 2023, then soared by 125.84% to $7.2 million in 2024, then advanced by 8.48% to $7.8 million in 2025, then slipped by 6.08% to $7.4 million in 2026.
• Business Quant data shows VYGR's Current Leases at $7.4 million in Q1 2026, $7.8 million in Q4 2025, and $7.8 million in Q3 2025.